Genelux (GNLX) Operating Expenses (2022 - 2026)
Genelux (GNLX) posted quarterly Operating Expenses of $9.2 million for Q1 2026, up 17.34% year-over-year from $7.8 million in Q1 2025, and down 2.64% quarter-over-quarter from $9.4 million in Q4 2025.
Genelux (GNLX) Operating Expenses (2022 - 2026) Analysis & Trends
Genelux's Operating Expenses history runs 5 years deep, the most recent figure standing at $9.2 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 17.34% year-over-year to $9.2 million; the TTM figure through Mar 2026 stood at $34.6 million (up 10.13% YoY), while the FY2025 annual figure was $33.2 million, up 4.79% from the prior year.
- Operating Expenses for Q1 2026 stood at $9.2 million, down from $9.4 million in the prior quarter.
- The five-year high for Operating Expenses was $9.7 million in Q4 2024, with the low at $3.2 million in Q4 2022.
- The 5-year median for Operating Expenses is $7.0 million (2023), against an average of $7.1 million.
- The sharpest annual moves came in 2023 and 2025: Operating Expenses surged 121.41% in 2023, then fell 3.78% in 2025.
- Genelux's Operating Expenses stood at $3.2 million in 2022, then jumped by 121.41% to $7.0 million in 2023, then jumped by 39.24% to $9.7 million in 2024, then slipped by 3.36% to $9.4 million in 2025, then retreated by 2.64% to $9.2 million in 2026.
- Business Quant data shows GNLX's Operating Expenses at $9.2 million in Q1 2026, $9.4 million in Q4 2025, and $8.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Genelux | 120.53 Mn | 120.53 Mn | - | 9.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.17 Mn |
| Dec 31, 2025 | 9.42 Mn |
| Sep 30, 2025 | 8.19 Mn |
| Jun 30, 2025 | 7.79 Mn |
| Mar 31, 2025 | 7.82 Mn |
| Dec 31, 2024 | 9.75 Mn |
| Sep 30, 2024 | 6.94 Mn |
| Jun 30, 2024 | 6.89 Mn |
| Mar 31, 2024 | 8.12 Mn |
| Dec 31, 2023 | 7.00 Mn |
| Sep 30, 2023 | 5.31 Mn |
| Jun 30, 2023 | 5.40 Mn |
| Mar 31, 2023 | 6.63 Mn |
| Dec 31, 2022 | 3.16 Mn |
| Sep 30, 2022 | 4.66 Mn |